Comparing two conditioning regimens for stem cell transplantation in adult leukemia patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effects of two conditioning regimens, Total Body Irradiation (TBI) and Total Marrow, Central Nervous System and Lymphoid Irradiation (TMLI), on adults with acute lymphoblastic leukemia (ALL) undergoing haploidentical stem cell transplantation. The study aims to determine which regimen more effectively eliminates leukemia cells while minimizing damage to normal tissues. Participants will be randomly assigned to receive either TBI or TMLI, with the goal of improving survival outcomes and quality of life. The trial is designed to provide evidence for the optimal conditioning approach in this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Informed Consent: Participants must voluntarily sign a written informed consent form.
2. Age and Gender: Participants should be male or female, aged 18-65 years, inclusive.
3. Diagnosis: Participants must be diagnosed with acute lymphoblastic leukemia (ALL) according to World Health Organization (WHO) criteria, and the diagnosis must apply to adults aged 18-65 years.
4. Remission Status: The participant's leukemia must be in hematologic remission (complete remission, CR) prior to transplantation.
5. Donor Availability: There must be a suitable haploidentical donor available, and the participant must consent to undergo haploidentical hematopoietic stem cell transplantation (haplo-HSCT).
6. Karnofsky Performance Status: The participant must have a Karnofsky score of 70 or higher, indicating that they are capable of caring for themselves and carrying out normal activities. Additionally, they must not have significant organ dysfunction, defined by the following:

   * Cardiac Function: New York Heart Association (NYHA) classification of class II or lower.
   * Liver Function: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels should be no more than 2.5 times the upper limit of normal. Bilirubin levels should be no more than 2 times the upper limit of normal.
   * Renal Function: Serum creatinine levels should be no more than 1.5 times the upper limit of normal, or the creatinine clearance rate should be at least 60 ml/min.
   * Pulmonary Function: Participants should not experience significant dyspnea, should not require oxygen therapy, should not have interstitial lung disease, and should not have any active pulmonary infections.
7. Reproductive Health:

   * Women of childbearing potential must test negative for pregnancy with a Human Chorionic Gonadotropin (HCG) test, confirmed by immunofluorescence during both screening and baseline periods. They must also agree to use effective contraception for at least one year following the transplantation.
   * Male participants with female partners of childbearing potential must agree to use effective barrier contraception and refrain from sperm donation for at least one year following the transplantation.

Exclusion Criteria:

To be eligible for inclusion in the study, participants must not meet any of the following criteria:

1. The patient has not achieved hematologic remission before transplantation.
2. The patient has chosen a non-haploidentical related donor.
3. The patient has severe cardiac, hepatic, renal, or pulmonary diseases that make them unable to tolerate the conditioning regimen.
4. The patient has an active or refractory infection, or other life-threatening complications.
5. The patient has a history of other malignant tumors, psychiatric disorders, or HIV infection.
6. The patient refuses to sign the informed consent form, is unwilling to comply with clinical follow-up required by the study, or does not consent to the use of their data to support future research, project presentations, and clinical practices.
7. The investigator deems the patient unsuitable for participation in the study for any other reason.

Where it's running

• The First Affiliated Hospital of Zhengzhou University
  Zhengzhou, Henan, China Recruiting

Study contacts

• Principal investigator: Xiangbo Wan, PhD. — The First Affiliated Hospital of Zhengzhou University
• Study coordinator: Zhilei Bian, PhD.
• Email: bianzhilei@zzu.edu.cn
• Phone: +86037166862278

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pediatric-style chemotherapy with venetoclax and immunotherapy for adults with Ph-negative acute lymphoblastic leukemia

  This treatment plan tests whether pediatric-style chemotherapy combined with venetoclax and optional immunotherapy helps people aged 14–60 with newly diagnosed Ph-negative ALL achieve remission and clear minimal residual disease.

  Recruiting Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07495631

• Combined chemotherapy with venetoclax and stem cell transplant for adults with Ph-negative ALL

  This trial will try a treatment plan that gives intensive chemotherapy including venetoclax, followed by consolidation chemotherapy and possible allogeneic stem cell transplant, for adults aged 18–60 with Philadelphia chromosome–negative acute lymphoblastic leukemia.

  Recruiting Phase 2/3 Shanxi Bethune Hospital · Taiyuan, Shanxi · NCT07059156

• Comparing two conditioning regimens for stem cell transplantation in adult leukemia patients

  This study is testing which of two treatment methods, Total Body Irradiation or Total Marrow Irradiation, works better for adults with leukemia getting stem cell transplants to kill cancer cells while causing less harm to healthy tissue.

  Recruiting Phase 2 The First Affiliated Hospital of Zhengzhou University · Zhengzhou, Henan · NCT06557161

• Combining chemotherapy with CAR-T cell therapy for newly diagnosed adult patients with Philadelphia Chromosome Negative ALL

  This study is testing if combining CAR-T cell therapy with chemotherapy can help adults newly diagnosed with Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia feel better and live longer.

  Recruiting Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT06481241

• Combining CAR-T therapy with chemotherapy for newly diagnosed Ph+ acute lymphoblastic leukemia

  This study is testing a new treatment that combines CAR-T therapy with chemotherapy to see if it can help adults with newly diagnosed Ph+ acute lymphoblastic leukemia feel better and live longer.

  Recruiting Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT06481228

• Evaluating TGRX-814 in patients with blood cancers

  This study is testing a new drug called TGRX-814 to see if it is safe and effective for people with blood cancers like lymphoma and leukemia.

  Recruiting Phase 1/2 Shenzhen TargetRx Co., Ltd. · Tianjin, Tianjin Municipality · NCT06206174

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.